I would say that lots of interesting things are happening in biotech, and these things are slowly building critical mass, similar to what happened in computer hardware during the period 1970-2000.
Genomic platforms are now able to capture multiple measurements (e.g. RNA and chromatin openness) from single cells in large tissue slices/massive perturbation experiments.
Once time gets baked into the equation, we will be able to build better models of systems biology. However, human trials will still be a major bottleneck.
Genomic platforms are now able to capture multiple measurements (e.g. RNA and chromatin openness) from single cells in large tissue slices/massive perturbation experiments.
Once time gets baked into the equation, we will be able to build better models of systems biology. However, human trials will still be a major bottleneck.